CryoCor, Inc. Announces Webcast And Conference Call Of Year End Results And Clinical Update

SAN DIEGO, Feb. 2 /PRNewswire-FirstCall/ -- CryoCor, Inc. , a medical device company focused on the treatment of cardiac arrhythmias, announced today that it will release its financial results for the year ended December 31, 2006 on Thursday, February 15, 2007 after the close of the U.S. financial markets.

CryoCor will also hold a Web cast and conference call at 5:00 p.m. EST / 2:00 p.m. PST on February 15, 2007 to discuss the financial results, the status of its clinical initiatives, and the status of its discussions with the FDA regarding its application for pre-market approval for the treatment of atrial flutter. The dial-in numbers are 1-877-407-4018 for domestic callers, and 1-201-689-8471 for international callers. A live Web cast of the conference call will be available online from the investor relations page of the Company’s corporate Web site at www.cryocor.com.

After the live Web cast, the call will remain available on CryoCor’s Web site for at least 30 days following presentation. In addition, a telephonic replay of the call will be available. The replay dial-in numbers are 1-877-660-6853 for domestic callers 1-201-612-7415 for international callers. Please use account number 3055 and conference ID number 230674.

About CryoCor

CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company’s product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of AF and AFL, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of AF. For more information please visit the Company’s website at http://www.cryocor.com

Contacts: CryoCor Gregory J. Tibbitts Chief Financial Officer (858) 909-2200 gtibbitts@cryocor.com The Ruth Group Stephanie Carrington / Nick Laudico (investors) (646) 536-7017 / 7030 scarrington@theruthgroup.comnlaudico@theruthgroup.com Jason Rando (media) (646) 536-7025 jrando@theruthgroup.com

CryoCor, Inc.

CONTACT: CryoCor - Gregory J. Tibbitts, Chief Financial Officer, +1-858-909-2200, gtibbitts@cryocor.com; The Ruth Group - Investors, StephanieCarrington, +1-646-536-7017, scarrington@theruthgroup.com, or Nick Laudico,+1-646-536-7030, nlaudico@theruthgroup.com, or Media, Jason Rando,+1-646-536- 7025, jrando@theruthgroup.com

MORE ON THIS TOPIC